Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism
Youichi Ohno, Masakatsu Sone, Nobuya Inagaki, et al.
Hypertension (2018) Vol. 71, Iss. 3, pp. 530-537
Open Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Satoshi Umemura, Hisatomi Arima, Shuji Arima, et al.
Hypertension Research (2019) Vol. 42, Iss. 9, pp. 1235-1481
Open Access | Times Cited: 1536
Diagnosis and treatment of primary aldosteronism
Martín Reincke, Irina Bancos, Paolo Mulatero, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 12, pp. 876-892
Closed Access | Times Cited: 204
Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021
Mitsuhide Naruse, Takuyuki Katabami, Hirotaka Shibata, et al.
Endocrine Journal (2022) Vol. 69, Iss. 4, pp. 327-359
Open Access | Times Cited: 139
Aldosterone as a Mediator of Cardiovascular Damage
Fabrizio Buffolo, Martina Tetti, Paolo Mulatero, et al.
Hypertension (2022) Vol. 79, Iss. 9, pp. 1899-1911
Open Access | Times Cited: 106
Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension ∗
Paolo Mulatero, Leonardo A. Sechi, Tracy Ann Williams, et al.
Journal of Hypertension (2020) Vol. 38, Iss. 10, pp. 1929-1936
Closed Access | Times Cited: 101
Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit
Jacopo Burrello, Silvia Monticone, Isabel Losano, et al.
Hypertension (2020) Vol. 75, Iss. 4, pp. 1025-1033
Open Access | Times Cited: 94
Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism
Graeme Eisenhofer, Claudio Durán, Carlo Vittorio Cannistraci, et al.
JAMA Network Open (2020) Vol. 3, Iss. 9, pp. e2016209-e2016209
Open Access | Times Cited: 73
Primary Aldosteronism: State-of-the-Art Review
Anand Vaidya, Gregory L. Hundemer, Kazutaka Nanba, et al.
American Journal of Hypertension (2022) Vol. 35, Iss. 12, pp. 967-988
Open Access | Times Cited: 65
Left ventricular remodeling and dysfunction in primary aldosteronism
Cheng‐Hsuan Tsai, Chien‐Ting Pan, Yi‐Yao Chang, et al.
Journal of Human Hypertension (2020) Vol. 35, Iss. 2, pp. 131-147
Open Access | Times Cited: 67
The Effect of Aldosterone on Cardiorenal and Metabolic Systems
Hiromasa Otsuka, Masanori Abe, Hiroki Kobayashi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5370-5370
Open Access | Times Cited: 22
Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism
Takuyuki Katabami, Hisashi Fukuda, Hidekazu Tsukiyama, et al.
Journal of Hypertension (2019) Vol. 37, Iss. 7, pp. 1513-1520
Closed Access | Times Cited: 52
Genetic causes of primary aldosteronism
Eric Seidel, Julia Schewe, Ute I. Scholl
Experimental & Molecular Medicine (2019) Vol. 51, Iss. 11, pp. 1-12
Open Access | Times Cited: 49
Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism
Kyoko Teruyama, Mitsuhide Naruse, Mika Tsuiki, et al.
Journal of Human Hypertension (2021) Vol. 36, Iss. 1, pp. 77-85
Open Access | Times Cited: 35
Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism
Xiao Lin, Muhammad Hasnain Ehsan Ullah, Wu Xiong, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 8
Open Access | Times Cited: 26
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Nathan Mullen, James Curneen, Padraig Donlon, et al.
Endocrine Reviews (2023) Vol. 45, Iss. 1, pp. 125-170
Open Access | Times Cited: 16
International multicenter survey on screening and confirmatory testing in primary aldosteronism
Mitsuhide Naruse, Masanori Murakami, Takuyuki Katabami, et al.
European Journal of Endocrinology (2023) Vol. 188, Iss. 1, pp. 125-134
Open Access | Times Cited: 15
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Subodh Verma, Avinash Pandey, Arjun Pandey, et al.
AJP Heart and Circulatory Physiology (2023) Vol. 326, Iss. 3, pp. H670-H688
Closed Access | Times Cited: 15
Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review
Wei‐Ting Wang, Tsung-Hui Wu, Leay‐Kiaw Er, et al.
Hypertension Research (2024) Vol. 47, Iss. 5, pp. 1103-1119
Closed Access | Times Cited: 6
In situ metabolomics of aldosterone-producing adenomas
Masanori Murakami, Yara Rhayem, Thomas Kunzke, et al.
JCI Insight (2019) Vol. 4, Iss. 17
Open Access | Times Cited: 40
Clinical Characteristics and Postoperative Outcomes of Primary Aldosteronism in the Elderly
Masao Takeda, Kōichi Yamamoto, Hiroshi Akasaka, et al.
The Journal of Clinical Endocrinology & Metabolism (2018) Vol. 103, Iss. 10, pp. 3620-3629
Open Access | Times Cited: 39
Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism
Minoru Satoh, Tatsuya Maruhashi, Yuichi Yoshida, et al.
Hypertension Research (2019) Vol. 42, Iss. 6, pp. 817-824
Closed Access | Times Cited: 39
Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
Fumitoshi Satoh, Sadayoshi Ito, Hiroshi Itoh, et al.
Hypertension Research (2020) Vol. 44, Iss. 4, pp. 464-472
Open Access | Times Cited: 37
Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta‐analysis
Sicen Wu, Jun Yang, Jinbo Hu, et al.
Clinical Endocrinology (2019) Vol. 90, Iss. 5, pp. 641-648
Open Access | Times Cited: 36
Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism
Martin Wolley, Moe Thuzar, Michael Stowasser
Best Practice & Research Clinical Endocrinology & Metabolism (2020) Vol. 34, Iss. 3, pp. 101400-101400
Closed Access | Times Cited: 33
DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases
Yoshimichi Takeda, Masashi Demura, Takashi Yoneda, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4587-4587
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top